Mizuho Reiterates Buy Rating for LivaNova (NASDAQ:LIVN)

Mizuho reissued their buy rating on shares of LivaNova (NASDAQ:LIVNFree Report) in a report published on Wednesday, Benzinga reports. The brokerage currently has a $75.00 price target on the stock.

A number of other equities analysts also recently weighed in on the company. Robert W. Baird upped their target price on LivaNova from $56.00 to $62.00 and gave the company a neutral rating in a report on Thursday, February 22nd. Needham & Company LLC reiterated a buy rating and issued a $72.00 target price on shares of LivaNova in a report on Wednesday, March 20th. Finally, Barclays upped their target price on LivaNova from $57.00 to $61.00 and gave the company an equal weight rating in a report on Monday, February 26th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, LivaNova currently has an average rating of Moderate Buy and an average price target of $64.40.

Check Out Our Latest Stock Analysis on LivaNova

LivaNova Price Performance

LIVN stock opened at $55.87 on Wednesday. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44. LivaNova has a one year low of $41.87 and a one year high of $59.86. The firm has a market capitalization of $3.01 billion, a PE ratio of 174.60 and a beta of 0.89. The firm has a 50-day moving average of $52.03 and a two-hundred day moving average of $50.61.

LivaNova (NASDAQ:LIVNGet Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.10. LivaNova had a net margin of 1.53% and a return on equity of 12.23%. The company had revenue of $310.10 million during the quarter, compared to analyst estimates of $287.65 million. During the same period in the prior year, the firm earned $0.81 earnings per share. The business’s quarterly revenue was up 12.8% on a year-over-year basis. On average, analysts forecast that LivaNova will post 3.01 earnings per share for the current year.

Hedge Funds Weigh In On LivaNova

A number of hedge funds have recently added to or reduced their stakes in LIVN. Lazard Asset Management LLC acquired a new position in LivaNova in the second quarter worth approximately $46,000. Headlands Technologies LLC acquired a new position in LivaNova during the third quarter valued at approximately $72,000. Point72 Middle East FZE acquired a new position in LivaNova during the fourth quarter valued at approximately $72,000. Picton Mahoney Asset Management acquired a new position in LivaNova during the third quarter valued at approximately $91,000. Finally, US Bancorp DE grew its holdings in LivaNova by 12.4% during the second quarter. US Bancorp DE now owns 2,069 shares of the company’s stock valued at $106,000 after purchasing an additional 229 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Company Profile

(Get Free Report)

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.

See Also

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.